Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2121-2126, May 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tai, Y.-T.
Right arrow Articles by Cannistra, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tai, Y.-T.
Right arrow Articles by Cannistra, S. A.
[Cancer Research 59, 2121-2126, May 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

In Vivo Cytotoxicity of Ovarian Cancer Cells through Tumor-selective Expression of the BAX Gene1

Yu-Tzu Tai, Thomas Strobel, Donald Kufe and Stephen A. Cannistra2

Departments of Adult Oncology [Y-T. T., T. S., S. A. C.] and Cancer Pharmacology [D. K.], Dana-Farber Cancer Institute, and the Department of Hematology/Oncology, Beth Israel-Deaconess Medical Center [S. A. C.], Harvard Medical School, Boston, Massachusetts 02215

The BAX proapoptotic protein is capable of inducing cell death either directly, through its effects on mitochondrial function, or indirectly, by lowering the apoptotic threshold in response to certain chemotherapy agents. In this study, we tested the hypothesis that selective expression of BAX in human ovarian cancer through adenoviral gene transfer might represent a novel approach to eradicating tumor cells in vivo. Two constructs were prepared using replication-deficient adenoviral vectors containing either the cDNA for ß-galactosidase (Ad.DF3.ßGAL) or hemagglutinin (HA)-tagged BAX (Ad.DF3.BAX) under the control of the DF3 promoter. The DF3 promoter was used to confer tumor-specific gene expression in view of its restricted pattern of expression in the majority of human ovarian cancers and its limited expression in normal peritoneal mesothelial cells. In vitro infection of up to seven different epithelial cancer cell lines with Ad.DF3.ßGAL or Ad.DF3.BAX resulted in expression of either ß-galactosidase activity or HA-BAX protein, respectively, which was highly correlated with DF3 levels. Furthermore, infection with Ad.DF3.BAX was capable of highly selective cytotoxicity of DF3-positive ovarian cancer clonogenic cells in vitro. The effect of i.p. administration of Ad.DF3.BAX was also assessed in nude mice inoculated with the DF3-positive 36M2 human ovarian cancer cell line. Expression of either ß- galactosidase activity (after Ad.DF3.ßGAL treatment) or HA-BAX transcripts (after Ad.DF3.BAX treatment) was restricted to tumor tissue in vivo. Importantly, administration of Ad.DF3.BAX on days 2 and 3 after tumor inoculation was capable of eradicating >99% of tumor implants. These results demonstrate the feasibility of tumor selective expression of a proapoptotic protein such as BAX through adenoviral gene transfer.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Schwalm, J. F. Stevens, Z. Jiang, M. R. Schuyler, R. Schrader, S. H. Randell, F. H. Y. Green, and Y. Tesfaigzi
Expression of the proapoptotic protein Bax is reduced in bronchial mucous cells of asthmatic subjects
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1102 - L1109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Spentzos, D. A. Levine, S. Kolia, H. Otu, J. Boyd, T. A. Libermann, and S. A. Cannistra
Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer
J. Clin. Oncol., November 1, 2005; 23(31): 7911 - 7918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris
In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter
Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, K. Podar, N. Mitsiades, B. Lin, C. Mitsiades, D. Gupta, M. Akiyama, L. Catley, T. Hideshima, N. C. Munshi, et al.
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
Blood, April 1, 2003; 101(7): 2762 - 2769.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. N. Barnes, C. J. Coolidge, A. Hemminki, R. D. Alvarez, and D. T. Curiel
Conditionally Replicative Adenoviruses for Ovarian Cancer Therapy
Mol. Cancer Ther., April 1, 2002; 1(6): 435 - 439.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells
Blood, February 15, 2002; 99(4): 1419 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Tong, Q. Yang, C. Vater, L.K. Venkatesh, D. Custeau, T. Chittenden, G. Chinnadurai, and H. Gourdeau
The Pro-apoptotic Protein, Bik, Exhibits Potent Antitumor Activity That Is Dependent on Its BH3 Domain
Mol. Cancer Ther., December 1, 2001; 1(2): 95 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Casado, J. Gomez-Navarro, M. Yamamoto, Y. Adachi, C. J. Coolidge, W. O. Arafat, S. D. Barker, M. H. Wang, P. J. Mahasreshti, A. Hemminki, et al.
Strategies to Accomplish Targeted Expression of Transgenes in Ovarian Cancer for Molecular Therapeutic Applications
Clin. Cancer Res., August 1, 2001; 7(8): 2496 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Pataer, W. R. Smythe, R. Yu, B. Fang, T. McDonnell, J. A. Roth, and S. G. Swisher
Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines
J. Thorac. Cardiovasc. Surg., January 1, 2001; 121(1): 0061 - 67.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
When Is a ""Prognostic Factor"" Really Prognostic?
J. Clin. Oncol., November 15, 2000; 18(22): 3745 - 3747.
[Full Text] [PDF]

Home page
 JCOHome page
M. Baekelandt, R. Holm, J. M. Nesland, C. G. Trope, and G. B. Kristensen
Expression of Apoptosis-Related Proteins Is an Independent Determinant of Patient Prognosis in Advanced Ovarian Cancer
J. Clin. Oncol., November 15, 2000; 18(22): 3775 - 3781.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. W. Lowe and A. W. Lin
Apoptosis in cancer
Carcinogenesis, March 1, 2000; 21(3): 485 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kagawa, J. Gu, S. G. Swisher, L. Ji, J. A. Roth, D. Lai, L. C. Stephens, and B. Fang
Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines
Cancer Res., March 1, 2000; 60(5): 1157 - 1161.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.